Drug Discovery World

NOVEMBER 14, 2022

Minoryx and Neuraxpharm have agreed a strategic alliance to provide a new therapy for rare CNS disease patients in Europe. . The companies have entered into a license agreement for the European rights to leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD). .

Therapies 130

Therapies Disease Licensing Licensing 130

Drug Discovery World

SEPTEMBER 21, 2022

Otsuka Pharmaceutical’s Lupkynis (voclosporin) is the first oral treatment to be approved in Europe for the treatment of active lupus nephritis (LN) in adult patients. LN is a severe manifestation of systemic lupus erythematosus (SLE), a chronic and debilitating autoimmune disease that is suggested to cause irreversible nephron loss.

Treatment 130

Treatment Licensing Licensing Pharmaceuticals 130

Drug Discovery World

AUGUST 29, 2024

The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. Lecanemab is for slowing progression in mild cognitive impairment or mild dementia due to Alzheimer’s disease (AD) in adults.

Regulations 147

Regulations Hospitals Licensing Licensing 147

Drug Discovery World

NOVEMBER 21, 2022

The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for anti-CD3-directed antibody TZIELD (teplizumab-mzwv), the first immunomodulatory treatment for type 1 diabetes (T1D). . The company also offers financial assistance options to eligible patients for out-of-pocket costs. . .

FDA Approval 130

FDA Approval FDA Therapies Disease 130

Drug Discovery World

OCTOBER 4, 2022

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . With its recent award of $3.35 Overcoming sector challenges .

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

Licensing 52

Licensing Licensing Therapies Disease 52

Drug Discovery World

NOVEMBER 16, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the world’s first gene therapy for sickle-cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). Of these eligible patients, 28 (97%) were free of severe pain crises for at least 12 months after treatment.

Therapies 277

Therapies Clinical Trials Trials Treatment 277

The Pharma Data

OCTOBER 27, 2021

Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.

Licensing 52

Licensing Licensing Disease Small Molecule 52

Drug Target Review

SEPTEMBER 7, 2023

host disease risks. The first clinical candidate, BSB-1001, aims to transform leukemia treatment by targeting minor histocompatibility antigen-1. host disease (GVHD) in allogeneic hematopoietic stem cell transplants (alloSCT). leukaemia (GVL) effect while limiting graft-vs-host-disease.

Treatment 98

Treatment Licensing Licensing Disease 98

Drug Discovery World

FEBRUARY 16, 2024

It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy. New treatment options are needed to help the HS community find relief from the burden of this disease.”

Licensing 162

Licensing Licensing Treatment Disease 162

Drug Discovery World

FEBRUARY 9, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC). versus 11.5%).

Treatment 130

Treatment Clinical Research International FDA 130

Drug Discovery World

JULY 12, 2024

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 is an investigational adeno-associated virus 2 glial cell line-derived neurotrophic factor (AAV2-GDNF) neurorestorative gene therapy.

Therapies 147

Therapies Clinical Trials FDA Clinical Development 147

Drug Target Review

SEPTEMBER 5, 2024

This role gave me a good understanding of how important IP/patent and global marketing are for the brand but also the importance of emerging markets and co-development and out-licensing to other pharma companies. I experienced challenges in cultural differences working with US, UK, Japan, and China.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

Drug Target Review

APRIL 4, 2024

What are the key findings of the preclinical study regarding the neurophysiological brain state in a Parkinson’s disease psychosis (PDP) model? Treatment with mesdopetam counteracted both these features of the psychosis model, ie, restored normal levels of synchronisation and reduced HFOs. Visual hallucinations are common in PD.

Disease 105

Disease Treatment Licensing Licensing 105

Science Daily: Pharmacology News

AUGUST 9, 2023

The drug tecovirimat is currently in use for the treatment of mpox -- the disease caused by monkeypox virus -- that spread worldwide in 2022. Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus.

Licensing 48

Licensing Licensing Treatment Virus 48

LifeSciVC

JULY 17, 2024

By Mike Cloonan, Chief Executive Officer of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC The drug development process in rare diseases is rife with challenges especially when companies target significant differentiation or first-in-class targets.

Clinical Research 45

Clinical Research Disease Research Clinical Trials 45

Drug Discovery World

APRIL 11, 2024

The Scottish Medicines Consortium (SMC) has accepted GSK’s dostarlimab as a treatment for adult patients with endometrial cancer when used in combination with platinum-containing chemotherapy. This means that dostarlimab is the first immunotherapy treatment to be accepted for use within NHS Scotland for this group of eligible patients.

Therapies 130

Therapies Licensing Licensing Treatment 130

Drug Discovery World

JULY 11, 2023

We are confident that the strong collaboration of the experienced teams at Evotec and BMS will make novel innovative treatment options available to patients living with a broad range of neurodegenerative conditions.” Evotec and BMS aim to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

Licensing 189

Licensing Licensing Drugs Disease 189

Drug Discovery World

JANUARY 3, 2024

Takeda’s Livtencity (maribavir) has been approved in China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease.

Licensing 130

Licensing Licensing Trials Therapies 130

Drug Discovery World

FEBRUARY 1, 2024

GSK’s Omjjara (momelotinib) has been granted marketing authorisation in Great Britain for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Licensing 130

Licensing Licensing Production Trials 130

Drug Discovery World

AUGUST 24, 2022

A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments. . The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment.

Research 246

Research Clinical Trials Virus Trials 246

Conversations in Drug Development Trends

NOVEMBER 27, 2023

Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow. In June 2023, the U.S.

Treatment 75

Treatment FDA Clinical Trials Therapies 75

Drug Discovery World

JANUARY 4, 2023

Celltrion USA has submitted a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act for CT-P13 SC for the treatment of inflammatory bowel disease (IBD). To read this content in full, you need to login.

FDA 130

FDA Licensing Licensing Disease 130

Drug Discovery World

MARCH 7, 2024

It has potential to be the first approved treatment for HSCT-TMA, a rare complication of stem cell transplantation that has an 80% mortality rate among severe adult and paediatric patients. Akari’s long-acting version of nomacopan (PASylated-nomacopan) is in the final stages of pre-clinical development for geographic atrophy (GA).

Clinical Trials 147

Clinical Trials Licensing Licensing Clinical Development 147

Drug Discovery World

FEBRUARY 23, 2024

FDA approves first T cell therapy in solid tumours The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. £7M The post This week in drug discovery (19-23 February) appeared first on Drug Discovery World (DDW).

FDA Approval 130

FDA Approval Therapies Licensing Licensing 130

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.

Disease 49

Disease Pharmaceuticals Therapies Production 49

Drug Discovery World

JANUARY 10, 2024

AIO-001 was exclusively licensed to Aiolos outside of Greater China by Jiangsu Hengrui Pharmaceuticals. Tony Wood, Chief Scientific Officer, GSK, said: “We have a proud heritage and deep development expertise in respiratory medicines, especially addressing diseases driven by IL-5 with high levels of eosinophils or high T2 inflammation.

Pharmacokinetics 130

Pharmacokinetics Licensing Licensing Clinical Development 130

Drug Discovery World

MARCH 25, 2024

Allogene Therapeutics and Arbor Biotechnologies Biotechnology companies Allogene Therapeutics and Arbor Biotechnologies entered a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s AlloCAR T platform for the treatment of autoimmune disease (AID).

Drugs 130

Drugs Licensing Licensing Laboratories 130

The Pharma Data

JANUARY 12, 2021

13, 2021 /PRNewswire/ — EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. EVOQ Therapeutics today announced a license and collaboration agreement with Amgen. ANN ARBOR, Mich. , www.evoqtherapeutics.com.

Licensing 52

Licensing Licensing Biosimilars Clinical Development 52

Drug Discovery World

JUNE 1, 2023

According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1. Under the terms of the licensing agreement, AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

OCTOBER 7, 2022

The MHRA has granted marketing authorisation for Eli Lilly’s baricitinib (Olumiant), the first licensed JAK inhibitor for the treatment of severe alopecia areata in adult patients. . This is an important authorisation for patients as previously there has never been a licensed oral therapy for adults with severe alopecia areata.” .

Therapies 130

Therapies Licensing Licensing Treatment 130

The Pharma Data

MARCH 31, 2023

AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive CMG901 is being developed for the treatment of solid tumours that express the cell surface protein Claudin 18.2, including gastric cancers.

Licensing 40

Licensing Licensing Small Molecule Drugs 40

BioPharma Drive: Drug Pricing

JUNE 4, 2024

The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.

Licensing 70

Licensing Licensing Treatment Disease 70

Drug Discovery World

NOVEMBER 25, 2022

Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. FDA approves first disease-modifying therapy for T1D . Hope for drug that slows neurodegenerative disease . The top stories: .

FDA Approval 130

FDA Approval FDA Drugs Therapies 130

Drug Discovery World

AUGUST 4, 2023

Boehringer Ingelheim and CDR-Life entered a collaboration and licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate in September 2021. GA is a progressive, irreversible retinal disease and one of the leading causes of blindness in people over 65 years of age.

Licensing 130

Licensing Licensing Drugs Disease 130

Drug Discovery World

JANUARY 15, 2024

The NVIDIA DGX SuperPOD will be installed at Amgen’s deCODE genetics’ headquarters in Reykjavik, Iceland and will be used to build a human diversity atlas for drug target and disease-specific biomarker discovery. Chiesi and Oak Hill Bio intend to continue a Phase IIb clinical trial in 2024 in the United States, Europe, and Japan.

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

Drug Discovery World

FEBRUARY 6, 2023

Mesoblast has resubmitted its biologics license application (BLA) to the US Food and Drug Administration (FDA) for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).

FDA 130

FDA FDA Approval Therapies Licensing 130